Seliforant - Sensorion

Drug Profile

Seliforant - Sensorion

Alternative Names: SENS-111; UR-63325

Latest Information Update: 26 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palau Pharma
  • Developer Palau Pharma; Sensorion
  • Class Antiallergics; Antiasthmatics; Antihistamines; Azetidines; Pyrimidines; Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Vertigo
  • Preclinical Tinnitus
  • No development reported Asthma; Seasonal allergic rhinitis

Most Recent Events

  • 18 Oct 2018 Sensorion expects a regulatory approval to reduce patient sample size from 207 to around 100 patients for a phase II trial in acute unilateral vestibulopathy, by the end of 2018
  • 24 Jul 2018 Sensorion initiates enrolment in a phase II trial for Vertigo in Netherlands (EudraCT2018-000777-80)
  • 08 Jun 2018 Phase-II clinical trials in Vertigo (In volunteers) in Netherlands (PO) (EudraCT2018-000777-80)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top